Learning Unified Hyper-Network for Multi-Modal MR Image Synthesis and Tumor Segmentation With Missing Modalities

Scalable Swin Transformer network for brain tumor segmentation from incomplete MRI modalities

BACKGROUND

Deep learning methods have shown great potential in processing multi-modal Magnetic Resonance Imaging (MRI) data, enabling improved accuracy in brain tumor segmentation. However, the performance of these methods can suffer when dealing with incomplete modalities, which is a common issue in clinical practice. Existing solutions, such as missing modality synthesis, knowledge distillation, and architecture-based methods, suffer from drawbacks such as long training times, high model complexity, and poor scalability.

METHOD

This paper proposes IMS2Trans, a novel lightweight scalable Swin Transformer network by utilizing a single encoder to extract latent feature maps from all available modalities. This unified feature extraction process enables efficient information sharing and fusion among the modalities, resulting in efficiency without compromising segmentation performance even in the presence of missing modalities.

RESULTS

Two datasets, BraTS 2018 and BraTS 2020, containing incomplete modalities for brain tumor segmentation are evaluated against popular benchmarks. On the BraTS 2018 dataset, our model achieved higher average Dice similarity coefficient (DSC) scores for the whole tumor, tumor core, and enhancing tumor regions (86.57, 75.67, and 58.28, respectively), in comparison with a state-of-the-art model, i.e. mmFormer (86.45, 75.51, and 57.79, respectively). Similarly, on the BraTS 2020 dataset, our model scored higher DSC scores in these three brain tumor regions (87.33, 79.09, and 62.11, respectively) compared to mmFormer (86.17, 78.34, and 60.36, respectively). We also conducted a Wilcoxon test on the experimental results, and the generated p-value confirmed that our model's performance was statistically significant. Moreover, our model exhibits significantly reduced complexity with only 4.47 M parameters, 121.89G FLOPs, and a model size of 77.13 MB, whereas mmFormer comprises 34.96 M parameters, 265.79 G FLOPs, and a model size of 559.74 MB. These indicate our model, being light-weighted with significantly reduced parameters, is still able to achieve better performance than a state-of-the-art model.

CONCLUSION

By leveraging a single encoder for processing the available modalities, IMS2Trans offers notable scalability advantages over methods that rely on multiple encoders. This streamlined approach eliminates the need for maintaining separate encoders for each modality, resulting in a lightweight and scalable network architecture. The source code of IMS2Trans and the associated weights are both publicly available at https://github.com/hudscomdz/IMS2Trans.

Graph-Based Fusion of Imaging, Genetic and Clinical Data for Degenerative Disease Diagnosis

Graph learning methods have achieved noteworthy performance in disease diagnosis due to their ability to represent unstructured information such as inter-subject relationships. While it has been shown that imaging, genetic and clinical data are crucial for degenerative disease diagnosis, existing methods rarely consider how best to use their relationships. How best to utilize information from imaging, genetic and clinical data remains a challenging problem. This study proposes a novel graph-based fusion (GBF) approach to meet this challenge. To extract effective imaging-genetic features, we propose an imaging-genetic fusion module which uses an attention mechanism to obtain modality-specific and joint representations within and between imaging and genetic data. Then, considering the effectiveness of clinical information for diagnosing degenerative diseases, we propose a multi-graph fusion module to further fuse imaging-genetic and clinical features, which adopts a learnable graph construction strategy and a graph ensemble method. Experimental results on two benchmarks for degenerative disease diagnosis (Alzheimers Disease Neuroimaging Initiative and Parkinson's Progression Markers Initiative) demonstrate its effectiveness compared to state-of-the-art graph-based methods. Our findings should help guide further development of graph-based models for dealing with imaging, genetic and clinical data.